目的: BRAF/NRAS mutations are predictors of poor prognosis in melanoma.High-dose interferon (HDI) is the only drug approved by FDA as adjuvant therapy in hig
目的: Everolimus, an oral mTOR inhibitor, has shown minimal activity as a single agent in patients with metastatic melanoma unselected for potential predicti
Objective: NIVO is a programmed death-1 (PD-1) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs ove
Objective: Combined blockade of T-cell checkpoints by NIVO and IPI demonstrated a high objective response rate (ORR), promising overall survival (OS) and a
Objective: To observe and analyze the retinopathy associated with high doses of interferon α-2b therapy in patients with melanomas of the skin.Method: Eigh